The G-protein-coupled-receptor 30 (GPR30) is a new membrane estrogen receptor. The aim of the present study was to determine the correlations among GPR30, ERα, PR, C-erbB-2, p53, TNM stage, and pathologic grade in breast carcinomas. Two hundred forty-one biopsy specimens were evaluated with immunohistochemical assays, and then correlations were analyzed. Low negative correlations of GPR30 with ERα (r = -0.144, P<0.05) and PR (r = -0.214, P<0.01) were observed. Associations of GPR30 with C-erbB-2, p53, TNM stage, and pathologic grade were not confirmed. These findings indicated that GPR30 might be an independent prognostic factor in breast carcinomas.
Introduction
Estrogen is involved in the regulation of a wide array of biological processes. Early studies have identified three types of nuclear estrogen receptor (ER), ERα, ERβ, and ERγ, which function as hormone-dependent transcription factors (1-3). Estrogen promotes the development of the mammary gland and the growth of tumors arises from this tissue. Blocking the estrogen-binding sites is an effective approach to inhibit the growth of breast tumors with ER expression. Endocrine therapy for ER-positive breast cancers has been widely accepted. However, about 1/4 ER-positive cancers respond to ER antagonist poorly (4). The existence of an alternative ER, which can not be blocked by an antagonist, has been offered as an interpretation. This leads to the discovery of GPR30, which is detected in a variety of tissues. Tamoxifen and ICI 182,780 are not antagonists, but agonists for GPR30 (5). Recent studies have shown that GPR30 was involved in the estrogenmediated activation of adenylylcyclase and the release of heparan-bound epithelial growth factor (EGF) from breast cancer cells (6). GPR30 also participates in apoptosis and the modulation of cell cycle attributable to estrogens (7-9).
GPR30 plays an important role in the proliferation and apoptosis of tumor cells. As a hormone sensitive tumor, the growth of breast cancers is regulated by estrogens; GPR30 might play a role in the behavior of breast cancers. ER, PR (progesterone receptor), C-erbB-2, p53, TNM (tumor, nodes, and metastases) stage, and pathologic grade are important determinants for the prognosis and treatment of breast cancers. Of those three ERs, ERα has been clinically accepted as a prognostic factor; however, the predictive values of ERβ and ERγ remain unclear for lack of comprehensive info (10). Thus, only ERα was considered in this study.
The aim of the present study was to determine the correlation between GPR30 and clinicopathologic variables in breast carcinomas. 
Materials and Methods

Tissue Specimens
Two hundred forty-one paraffin-embedded, formalin-fixed biopsy specimens of breast carcinomas, including 226 infiltrating ductal carcinomas, 9 adencarcinomas, and 6 infiltrating lobular carcinomas were provided by the Department of Pathology, Chongqing Medical University (Chongqing, China). All patients were diagnosed and received surgical interventions in the First Affiliated Hospital of Chonqing Medical University during 2006-2007. ERα, PR, C-erbB-2, and p53 were simultaneously detected with immunohistochemical assays using monoclonal antibodies (Ascend Biotechnol. Co., Guangzhou, China), when performing post-operationally pathological examinations. These procedures were accomplished by clinical pathologists and sections were evaluated. Clinical TNM staging was performed according to post-operation data, using the criteria of International Union against Cancer (UICC, 1988) .
This study was approved by the University Committee.
Detection of GPR30 with Immunohistochemical Assay
Streptavidin-peroxidase (SP) assay (Invitrogen, Camarillo, CA) was used. Tissues were deparaffinized, and the endogenous peroxidase activity was quenched with 3% H 2 O 2 . Nonspecific binding sites were blocked with goat serum after recovering antigens. Rabbit anti-GPR30 polyclonal antibodies (Abcam, Cambridge, MA) were pipetted onto slides and kept overnight at 4 ºC. Slides were rinsed with phosphate buffered saline (PBS); horseradish peroxidase-conjugated goat antirabbit IgG was dropped and incubated for 15 minutes. Slides were washed with PBS, 3,3-daiminobenzidine tetrahydrochloride (DAB) added, and counterstained with hematoxylin.
Evaluation of the Immunostaining Pattern for GPR30
Sections were inspected under a microscope. The expression of GPR30 was ranked according to the percentage of positive cells and the intensity of coloration. For the percentage of positive-stain cells: 0 score, <10%; 1 score, 10-25%; 2 score, 25-50%; 3 score, >50%. As to the intensity of coloration: 0 score, negative; 1 score, buff; 2 score, yellow; 3 score, brown. The total score was calculated, and then the expression was ranked. The criterion was as follows: -, 0; +, l-2; ++, 3-4; +++, 5-6.
Statistics
All data were processed with the statistic software SPSS. Associations among GPR30, ERα, C-erbB-2, p53, TNM stage, and pathologic grade were evaluated with Spearman's rank correlation test. The critical value was set P<0.05.
Results
Distribution of GPR30
GPR30 was detected in cytoplasma ( Figs. 1-2) , and the pattern of expression was listed in Table I .
Associations Between GPR30 and Clinicopathologic Variables
Clinicopathologic variables, including TNM stage, pathological grade, ERα, PR, C-erbB-2, and p53, were listed in Tables II-IV. No associations were observed between GPR30 and C-erbB-2, p53, clinical stage, and pathologic grade. Correlations existed between GPR30 and ERα (r = -0.144; P = 0.026) and PR (r = -0.214; P = 0.001). ERα showed significant relationships with PR, C-erbB-2, clinical stage and pathologic grade (Table V) . 
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Discussion GPR30-positive cells showed a cytoplasmic staining pattern, which was consistent with previous findings (11). As a seven-transmembrane G-protein-coupled receptor, GPR30 was once believed to locate in plasma membrane. However, recent studies revealed that GPR30 existed in the endoplasmic reticulum/Golgi (12) . Estrogens were the lipophilic ligands with membrane-permeable potential, making GPR30 transmit signals as a G-protein-coupled receptor.
ERα, PR, C-erbB-2, p53, TNM stage, and pathologic grade were important prognostic factors for breast cancers. These factors were therefore detected and their correlations with GPR30 were evaluated. Higher expressions of ERα and PR implied a better prognosis. A negative correlation between GPR30 and ERα was found in this study. This differed from previous findings, in which a positive correlation between GPR30 and ER was manifested (13, 14) . PR also showed a negative correlation with GPR30 in the present study. Kuo et al. reported a positive correlation between GPR30 and PR, but this was not confirmed in an investigation performed by Filardo et al. (13, 14) . What led to the difference remained unclear. The present study was performed in Chinese women. Thus, there might be racial differences in the expression of GPR30. Smith et al. reported a negative correlation between GPR30 and PR in endometrial carcinomas (15). The pattern of GPR30 expression might vary between cancer types, which needed further investigations.
17β-estradiol triggered the release of heparan-bound EGF and induces tyrosyl phosphorylation of EGF receptors, which were mediated via coupling GPR30 (16) . No correlation between GPR30 and C- erbB-2 was found in this study. Kuo et al. reported an insignificant negative correlation between GPR30 and C-erbB-2 (13). . The disagreement should be explored. Unlike GPR30, ERα was negatively correlated with C-erbB-2, and this was consistent with previous findgings (13) . p53, as an independent prognostic factor for breast cancer, showed no correlation with GPR30. Thus, GPR30 affected the behavior of breast cancers via different pathways.
Clinical stage and pathologic grade were important prognostic determinants. The present findings did not confirm a correlation between GPR30 and the clinical/pathological grade. The number of stage III cases was small in this study, and this might led to a bias. Larger-scale trials were needed to determine the relationship between GPR30 and TNM stage. GPR30 was not correlated with C-erbB-2, p53, and clinical and pathological stages. These data suggested that GPR30 was an independent prognostic determinant.
The status of ER predicted the response to endocrine therapy in breast cancers (17). The role of GPR30 in anti-estrogen treatment needed to be explored. GPR30 also should be compared with ER in clinical trials, which were performed in ER + /GPR30 + , ER + /GPR30 -, ER -/GPR30 + , and ER -/GPR30cases. An antagonist for GPR30 must be developed to treat GPR30-positive cancers, if which had distinct clinical behavior. For those ER + /GPR30 + tumors, the treatment efficiency of an ER antagonist should be balanced with that of a GPR30 blocker thus improving the clinical outcomes.
The duration of follow-up was short, thus the survival data were not available. This was a limitation of the present study. Patients must be followed, including responses to treatment and survival durations, thus determining the role of GPR30 in the development of breast cancers. This manner could also determine the value of GPR30 expression as a prognostic determinant.
